Leprosy Vaccine

An effective leprosy vaccine will save children like Marc Jun from a lifetime of suffering with this dreaded disease.

American Leprosy Missions is committed to bringing an END to leprosy by developing a leprosy vaccine that will stop this terrible disease before it even starts.

So in 2002, American Leprosy Missions began a partnership with the Infectious Disease Research Institute (IDRI) in Seattle, Washington to develop a vaccine for leprosy.

An investment of 17 years and more than $6 million has resulted in a vaccine that is finishing Phase Ia clinical safety trials in healthy human volunteers and headed into Phase Ib among people most at risk.

This is an exciting opportunity to partner with us to make a lasting difference in the world by opening the door to finally stopping this devastating disease.

Why is a leprosy vaccine needed?

  • This ancient disease is still disabling and isolating people.
  • Every two minutes someone is diagnosed with leprosy.
  • More than four million people in the world suffer from leprosy-related disabilities.
  • An effective vaccine will limit infection, prevent disease and reduce transmission.
  • A vaccine is the only way to end this terrible disease.

Thanks to your generous support, the leprosy vaccine Phase Ia clinical trial is nearing completion.

Why now?

  • This is the first leprosy-specific vaccine to go through Phase I clinical trials.
  • We believe this vaccine will be an exciting new way to stop the transmission of leprosy and the only way to protect people from the disease long term.
  • What’s more, the vaccine may protect against nerve damage, the most serious complication of leprosy.
  • The vaccine has received approval from the U.S. Food and Drug Administration.

Why you?

  • This is an historic opportunity to help end an ancient disease.
  • With your help, families will never have to hear the devastating news that they have leprosy, nor suffer its debilitating effects.
  • You can leave a lasting legacy for millions of people around the world.

Funds needed

This vaccine may be the most exciting breakthrough in leprosy treatment since the cure, multi-drug therapy, was launched in the 1980s. Together we have reached this historic moment. Thank you!

If you’d like to contribute to the leprosy vaccine, we only need $35,338 in order to finish the Phase Ia clinical trial.

Then we are launching Phase Ib clinical trial in Brazil. We have already received funding commitments of $1,695,000. So that leaves $1,203,548 needed over the next two years. Donate now.

Progress and next steps

  • August 2017:  Approved by Food and Drug Administration 
  • October 2017:  Started Phase Ia clinical trial
  • November 2017: Interim safety review successfully completed
  • January-March 2018:  Complete injections of second cohort; perform last blood draw; begin one-year follow-up period
  • June-December 2018:  Complete clinical sample processing; analyze data and clinical immunology
  • January-March 2019: Analyze data and clinical immunology; write clinical study report
  • April 2019:  Complete Phase Ia clinical trial
  • July 2019:  Possible start of two-year Phase Ib clinical trial in Brazil

Leprosy vaccine in the news

Nature, March 28, 2018 – LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis of M. leprae infection

Markets Insider, October 12, 2017 – Promising New Leprosy Vaccine Moves into Human Trials

Wisconsin State Journal, October 12, 2017 – Covance site of first human study of vaccine for leprosy

Join us – Together we can help end leprosy

By God’s grace and with your partnership, a vaccine will be able to spare children like Marc Jun the devastation and heartbreak of leprosy. Donate now to stop the suffering.